It’s only fair to share… Atilotrelvir, BDBM622370, GST-HG171 2850365-55-6, ALIGOS THERAPEUTICS, INC 511.5 C24H32F3N5O4 (1S,3S,4R)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-2-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]spiro[2-azabicyclo[2.2.1]heptane-5,1′-cyclopropane]-3-carboxamide Spiro[2-azabicyclo[2.2.1]heptane-5,1′-cyclopropane]-3-carboxamide, N-[(1S)-1-cyano-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]-2-[(2S)-3,3-dimethyl-1-oxo-2-[(2,2,2-trifluoroacetyl)amino]butyl]-, (1S,3S,4R)- Atilotrelvir (GST-HG171) is antiviral agent, can inhibit coronavirus, picornavirus and norovirus infection. SCHEME SYNTHESIS Patents are available for this chemical structure: https://patentscope.wipo.int/search/en/result.jsf?inchikey=GTRJFXDJASEGSW-KBCNZALWSA-N PATENT US20230312571, Embodiment 11 PATENT WO2023043816 EX 50 [0312] To a stirred mixture of (1R,4S,6S)-5-(tert-butoxycarbonyl)-5-azaspiro[bicyclo[2.2.1]heptane-2,1′-cyclopropane]-6-carboxylic acid (120 mg, 0.449 …
Category «Uncategorized»
Zamaporvint
It’s only fair to share… Zamaporvint RXC004, PHASE 2 1H-IMIDAZOLE-1-ACETAMIDE, 5-METHYL-N-(5-(2-PYRAZINYL)-2-PYRIDINYL)-4-(2-(TRIFLUOROMETHYL)-4-PYRIDINYL)- 5-METHYL-N-(5-(2-PYRAZINYL)-2-PYRIDINYL)-4-(2-(TRIFLUOROMETHYL)-4-PYRIDINYL)-1H-IMIDAZOLE-1-ACETAMIDE UNII M56M7CHN8E Molecular Weight 439.39 Formula C21H16F3N7O CAS No. 1900754-56-4 Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. Zamaporvint targete membrane-bound o-acyltransferase Porcupine and inhibited Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays a favorable pharmacokinetic profile and shows potent antiproliferative effects in Wnt ligand-dependent colorectal and …
ATICAPRANT
It’s only fair to share… ATICAPRANT JNJ-67953964, WHO 10582 1174130-61-0 BENZAMIDE, 4-(4-(((2S)-2-(3,5-DIMETHYLPHENYL)-1-PYRROLIDINYL)METHYL)PHENOXY)-3-FLUORO- C26H27FN2O2, 418.512 Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder.[2][3][4] A regulatory application for approval of the medication is expected to be submitted by 2025.[2] Aticaprant is taken by mouth.[1] Side effects of aticaprant include itching, …
ZASTAPRAZAN
It’s only fair to share… ZASTAPRAZAN 2133852-18-1 362.5 g/mol, C22H26N4O JAQBO; JP-1366; OCN-101; Zastaprazan citrate – Onconic Therapeutics, UNII-W9S9KZX5MD Highest Development Phases Zastaprazan (JP-1366) is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases. SCHEME Patent WO2018008929 PATENT KR1777971 //////////ZASTAPRAZAN, JAQBO, JP-1366, OCN-101, Zastaprazan citrate, Onconic Therapeutics, …
Deuruxolitinib
It’s only fair to share… Deuruxolitinib C17H18N6, 314.422 Fda approved Leqselvi, 7/25/2024, To treat severe alopecia areata C-21543, CTP 543, CTP-543, CTP543 (3r)-3-(2,2,3,3,4,4,5,5-d8)cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)propanenitrile 1h-pyrazole-1-propanenitrile, .beta.-(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-D8-ruxolitinib Ingredient UNII CAS InChI Key Deuruxolitinib phosphate 8VJ43S4LCM 2147706-60-1 JFMWPOCYMYGEDM-NTVOUFPTSA-N unii 0CA0VSF91Y Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata.[1] It is a Janus …
Zelatriazin
It’s only fair to share… Zelatriazin, C18H15F3N4O3, 392.3 g/mol 1929519-13-0 NBI-1065846 or TAK-041 Phase 2 (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide Zelatriazin (NBI-1065846 or TAK-041) is a small-molecule agonist of GPR139. It was developed for schizophrenia and anhedonia in depression but trials were unsuccessful and its development was discontinued in 2023.[1][2][3][4][5][6][7] SCHEME SYN WO2016081736 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016081736&_cid=P21-M0X9BK-38013-1 Example 2: (S)-2-(4-oxobenzo[d][l,2,3]triazin-3(4H)-yl)-N-(l-(4-(trifluoromethoxy)phenyl)ethyl)acetamide [0166] To a vial containing 2-(4-oxobenzo[d][l,2,3]triazin-3(4H)-yl)acetic acid (15 mg, …
Vorasidenib
It’s only fair to share… Vorasidenib6-(6-chloropyridin-2-yl)-N2,N4-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine CAS 1644545-52-7, C14H13ClF6N6, 414.74 FDA APPROVED, 8/6/2024, Voranigo, To treat Grade 2 astrocytoma or oligodendroglioma UNII 789Q85GA8P Ingredient UNII CAS InChI Key Vorasidenib citrate X478M962XG 2316810-02-1 YOUTVRFNJAAFNS-DLVAHKFUSA-N Vorasidenib citrate anhydrous W4XG3EQK7B 2316810-00-9 OCEHQNOYRLHJCI-WPRTUUMNSA-N Vorasidenib, sold under the brand name Voranigo, is an anti-cancer medication used for the treatment of certain forms of glioma.[1][2] Vorasidenib …
Arbemnifosbuvir, AT-752, PD160572
It’s only fair to share… Arbemnifosbuvir, AT-752, 1998705-63-7, PD160572 E9V7VHK36U INN 12706 C24H33FN7O7P 581.5 g/mol SYN propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate L-ALANINE, N-((P(R),2’R)-2-AMINO-2′-DEOXY-2′-FLUORO-N,2′-DIMETHYL-P-PHENYL-5′ -ADENYLYL)-, 1-METHYLETHYL ESTERN-((P(R),2’R)-2-AMINO-2′-DEOXY-2′-FLUORO-N,2′-DIMETHYL-P-PHENYL-5′ -ADENYLYL)-L-ALANINE 1-METHYLETHYL ESTER WO2022040473 Atea Pharmaceuticals, Inc. CN113784721 US20160257706 WO2022076903 US10874687 PATENT US20160257706 https://patentscope.wipo.int/search/en/detail.jsf?docId=US177601863&_cid=P11-M0VTE4-38538-1 Example 1. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate Step 1. Preparation of ((2R,3R,4R,5R)-3-(benzoyloxy)-5-bromo-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate (2) To a solution of (2R)-3,5-di-O-benzoyl-2-fluoro-2-C-methyl-D-ribono-γ-lactone (24.8 …
Zelicapavir
It’s only fair to share… Zelicapavir, Enanta Pharmaceuticals Alternative Names: EDP-938; EP 023938 cas 2070852-76-3 RSV-IN-7549.5 g/mol, C27H22F3N7O3 UNII U4OI721DMD (3S)-3-[[5-[3-morpholin-4-yl-5-(trifluoromethyl)pyridin-2-yl]-1,3,4-oxadiazol-2-yl]amino]-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one SYN New England Journal of Medicine (2022), 386(7), 655-666 WO2022157327 WO2018152413 WO2019067864 WO2017015449 PATENT WO2018152413 https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018152413&_cid=P20-M0V26A-30323-1 Step 5 : (<Sf)-3-((5-(3-morpholino-5-(trifluoromethyl)pyridin-2-yl)-1.3.4-oxadiazol-2- To a mixture of (5)-2-(3-morpholino-5-(trifluoromethyl)picolinoyl)-N-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [l,4]diazepin-3-yl)hydrazine-l-carboxamide (1.4 kg, 1 eq.) in DCM (11.2 L) in a …
Palopegteriparatide
It’s only fair to share… Palopegteriparatide Yorvipath , FDA 2024, 8/9/2024, To treat hypoparathyroidism Palopegteriparatide Palopegteriparatide is a human parathyroid hormone analogue corresponding to amino acid residues 1 – 34 of human parathyroid hormone, to which a methoxy polyethylene glycol (molecular weight: ca. 43,000) is bound via a cleavable linker (pegylation site: S1). Palopegteriparatide is …